Viking Therapeutics, Inc. (VKTX)


Viking Therapeutics, Inc. (VKTX)

$6.85 USD

0.42 (-5.78%)

Updated Sep 20 12:00am

Add VKTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 216 in Medical - Pharmaceuticals

See all “A” rated Strong Buy stocks

VKTX Daily Price Range
VKTX 52-Week Price Range

VKTX Stock Chart More Charts


VKTX Price/Volume Stats

Current price $6.85
Prev. close $7.27
Day low $6.58
Day high $7.35
50-day MA $7.37
200-day MA $8.19
52-week high $20.02
52-week low $6.53
Volume 9,199,100
Avg. volume 2,293,619
Dividend yield N/A
Market Cap 494.65M

Viking Therapeutics, Inc. (VKTX) Company Bio


Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.





VKTX News Stream


Event/Time News Detail
Loading, please wait...

VKTX Social Stream


Loading social stream, please wait...

View Full VKTX Social Stream

VKTX Returns

1-mo -2.28%
3-mo -14.48%
6-mo -16.77%
1-year -62.36%
3-year 431.01%
5-year N/A
YTD -10.46%
2018 88.42%
2017 241.18%
2016 -65.10%
2015 N/A
2014 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.4873 seconds.